The drug stops brain damage in the early stages of Alzheimer's

Scientists from the Feinstein Institute for Medical Research (new York, USA) tested a new drug to treat Alzheimer's disease in the early stages. The development of a severe neurodegenerative disease, which is manifested by memory loss and the progression of dementia, is associated with the accumulation of certain types of proteins in the brain.

In particular, a link has been established between Alzheimer's disease and increased concentration of Tau protein in brain tissues. The drug developed by scientists is a low-molecular-weight compound of plumb. The effectiveness of the new drug was tested on the so-called Tau-mice.  These are genetically modified animals that have an accumulation of human Tau peptides in their brains.

It turned out that the introduction of the drug helps to stop the accumulation of Tau protein in the brain and prevent damage to neurons at the earliest stage of Alzheimer's disease. The mice received the drug with food, they did not have any side effects from taking it. After a series of preclinical testing of new tools the study involving people will be conducted.